Gene Therapy-vMCO-010 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 301 | Macular dystrophy | 1 |
301. Macular dystrophy
Clinical trials : 46 / Drugs : 42 - (DrugBank : 11) / Drug target genes : 9 - Drug target pathways : 67
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05417126 (ClinicalTrials.gov) | July 5, 2022 | 9/6/2022 | Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease | A Phase 2a, Open Label Multicenter Clinical Trial to Evaluate the Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease | Stargardt Disease | Biological: Gene Therapy-vMCO-010 | Nanoscope Therapeutics Inc. | NULL | Active, not recruiting | 16 Years | N/A | All | 6 | Phase 2 | United States |